Antifungal agents in children.

[1]  C. Poets,et al.  Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome®) , 2007, Infection.

[2]  P. Coates,et al.  Pharmacokinetics of fluconazole in pediatric patients , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[3]  D. Gibbs,et al.  Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[4]  D. Denning,et al.  Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Thomas J Walsh,et al.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.

[7]  T. Walsh,et al.  A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Karlsson,et al.  Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration , 2004, Antimicrobial Agents and Chemotherapy.

[9]  W. Leisenring,et al.  Cyclophosphamide metabolism is affected by azole antifungals. , 2004, Blood.

[10]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Sirota,et al.  Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. , 2003, Journal of Antimicrobial Chemotherapy.

[12]  E. Leibovitz,et al.  High-Dose Liposomal Amphotericin B in the Therapy of Systemic Candidiasis in Neonates , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[13]  J. Mccormick,et al.  Retrospective study of the safety of caspofungin in immunocompromised pediatric patients , 2003, The Pediatric infectious disease journal.

[14]  J. Sobel,et al.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  C. A. Kauffman,et al.  Voriconazole: a new triazole antifungal agent. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  J. Perfect,et al.  Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.

[17]  S. Fook-Chong,et al.  Randomized trial of fluconazole versus low‐dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation , 2002, American journal of hematology.

[18]  Nina Singh,et al.  Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes , 2002, Antimicrobial Agents and Chemotherapy.

[19]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[20]  S. Piscitelli,et al.  Safety, Pharmacokinetics, and Pharmacodynamics of Cyclodextrin Itraconazole in Pediatric Patients with Oropharyngeal Candidiasis , 2002, Antimicrobial Agents and Chemotherapy.

[21]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[22]  H. Lazarus,et al.  Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study , 2002, Journal of clinical pharmacology.

[23]  J. L. Goodman,et al.  Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. , 2002, The American journal of medicine.

[24]  A. Sterrett,et al.  Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men , 2002, Antimicrobial Agents and Chemotherapy.

[25]  E. Thiel,et al.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Chodakewitz,et al.  Safety and tolerability of caspofungin acetate in the treatment of fungal infections , 2002, Transplant infectious disease : an official journal of the Transplantation Society.

[27]  J. Perfect,et al.  Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children , 2002, The Pediatric infectious disease journal.

[28]  E. Stone,et al.  Caspofungin: an echinocandin antifungal agent. , 2002, Clinical therapeutics.

[29]  F. Ikeda,et al.  Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. , 2002, The Journal of antibiotics.

[30]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[31]  K. Nelson,et al.  A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  R. Busuttil,et al.  Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. , 2002, Transplantation.

[33]  D. Kaufman,et al.  Fluconazole prophylaxis against fungal colonization and infection in preterm infants. , 2001, The New England journal of medicine.

[34]  E. Anaissie,et al.  Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected withAspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study , 2001, Antimicrobial Agents and Chemotherapy.

[35]  D. Denning,et al.  Muco‐cutaneous retinoid‐effects and facial erythema related to the novel triazole antifungal agent voriconazole , 2001, Clinical and experimental dermatology.

[36]  J. Graybill,et al.  THE ECHINOCANDINS, FIRST NOVEL CLASS OF ANTIFUNGALS IN TWO DECADES: WILL THEY LIVE UP TO THEIR PROMISE? , 2001, International journal of clinical practice.

[37]  W. Kreisel,et al.  A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  P. Deutsch,et al.  Drug interactions between caspofungin and tacrolimus , 2001 .

[39]  E. Ernst.  Investigational Antifungal Agents , 2001, Pharmacotherapy.

[40]  S. Piscitelli,et al.  Antifungal Pharmacodynamics: Concentration‐Effect Relationships in Vitro and in Vivo , 2001, Pharmacotherapy.

[41]  A. Hoang.  Caspofungin acetate: an antifungal agent. , 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[42]  J. Levron,et al.  Pharmacokinetics of Itraconazole Oral Solution in Neutropenic Children during Long-Term Prophylaxis , 2001, Antimicrobial Agents and Chemotherapy.

[43]  K. Lasseter,et al.  Effect of hepatic insufficiency on the pharmacokinetics of caspofungin , 2001 .

[44]  S. Piscitelli,et al.  Compartmental Pharmacokinetics of the Antifungal Echinocandin Caspofungin (MK-0991) in Rabbits , 2001, Antimicrobial Agents and Chemotherapy.

[45]  G. Leverger,et al.  Efficacy of Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in Immunosuppressed Paediatric Patients , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[46]  M. Ghannoum,et al.  New targets and delivery systems for antifungal therapy. , 2000, Medical mycology.

[47]  J. Graybill,et al.  Antifungal compounds: controversies, queries and conclusions. , 2000, Medical mycology.

[48]  B. D. Pauw.  New antifungal agents and preparations , 2000 .

[49]  M. Boeckh,et al.  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.

[50]  Janelle A Sabo,et al.  Voriconazole: A New Triazole Antifungal , 2000, The Annals of pharmacotherapy.

[51]  T. Tamaya,et al.  In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. , 2000, The Journal of antimicrobial chemotherapy.

[52]  H. Guchelaar,et al.  Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. , 2000, The Journal of antimicrobial chemotherapy.

[53]  D. Loebenberg,et al.  A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). , 2000, The Journal of antimicrobial chemotherapy.

[54]  B. Mogilner,et al.  Liposomal Amphotericin B (AmBisome) in the Treatment of Neonatal Candidiasis in Very Low Birth Weight Infants , 2000, Infection.

[55]  M. Ellis.  Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections? , 2000, Transplant infectious disease : an official journal of the Transplantation Society.

[56]  M. Mustafa,et al.  Use of amphotericin B colloidal dispersion in children. , 2000, Journal of pediatric hematology/oncology.

[57]  J. Perfect,et al.  Agents for treatment of invasive fungal infections. , 2000, Otolaryngologic clinics of North America.

[58]  T J Walsh,et al.  New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. , 2000, The oncologist.

[59]  W. Dismukes.  Introduction to antifungal drugs. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  J. Perfect,et al.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  Koji Kawabata,et al.  In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi , 2000, Antimicrobial Agents and Chemotherapy.

[62]  B. D. de Pauw.  New antifungal agents and preparations. , 2000, International journal of antimicrobial agents.

[63]  S. Dix,et al.  Lipid formulations of amphotericin B. , 2000, Current clinical topics in infectious diseases.

[64]  Katz.  Drug interactions of the newer oral antifungal agents , 1999, The British journal of dermatology.

[65]  S. Chanock,et al.  Amphotericin B lipid complex in pediatric patients with invasive fungal infections. , 1999, The Pediatric infectious disease journal.

[66]  V. Novelli,et al.  Safety and Tolerability of Fluconazole in Children , 1999, Antimicrobial Agents and Chemotherapy.

[67]  A. Prentice,et al.  A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies , 1999 .

[68]  E. Johnson,et al.  In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. , 1998, The Journal of antimicrobial chemotherapy.

[69]  M. Huttová,et al.  Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. , 1998, The Pediatric infectious disease journal.

[70]  T. Walsh,et al.  Antifungal Efficacy, Safety, and Single-Dose Pharmacokinetics of LY303366, a Novel Echinocandin B, in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits , 1998, Antimicrobial Agents and Chemotherapy.

[71]  E. Manavathu,et al.  Organism-Dependent Fungicidal Activities of Azoles , 1998, Antimicrobial Agents and Chemotherapy.

[72]  B. Guglielmo,et al.  Lipid formulations of amphotericin B: clinical efficacy and toxicities. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  E. Anaissie,et al.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[74]  R. Luke,et al.  Renal effects of amphotericin B lipid complex. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[75]  P. Jacqmin,et al.  Repeated-Dose Pharmacokinetics of an Oral Solution of Itraconazole in Infants and Children , 1998, Antimicrobial Agents and Chemotherapy.

[76]  A. Scarcella,et al.  Liposomal amphotericin B treatment for neonatal fungal infections. , 1998, The Pediatric infectious disease journal.

[77]  H. A. al Arishi,et al.  Liposomal amphotericin B in neonates with invasive candidiasis. , 1997, American journal of perinatology.

[78]  E. Manavathu,et al.  Organism-dependent fungicidal activity of azoles , 1997 .

[79]  J. Smith,et al.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) , 1997, Antimicrobial agents and chemotherapy.

[80]  R. Yeates,et al.  Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility , 1997, Mycoses.

[81]  J. Smith,et al.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis , 1997, Antimicrobial agents and chemotherapy.

[82]  H Kropp,et al.  Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872) , 1997, Antimicrobial agents and chemotherapy.

[83]  D. Debruyne.  Clinical Pharmacokinetics of Fluconazole in Superficial and Systemic Mycoses , 1997, Clinical pharmacokinetics.

[84]  Ronald N. Jones,et al.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans , 1997, Antimicrobial agents and chemotherapy.

[85]  J. Karlowsky,et al.  In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species , 1997, Antimicrobial agents and chemotherapy.

[86]  C. Douglas,et al.  Lipopeptide inhibitors of fungal glucan synthase. , 1997, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[87]  P. Cooper,et al.  Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. , 1996, The Pediatric infectious disease journal.

[88]  T. Walsh,et al.  Lipid formulations of amphotericin B: recent progress and future directions. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[90]  M. Levenstein,et al.  A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .

[91]  G. Lopez-Berestein,et al.  Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B , 1994, Antimicrobial Agents and Chemotherapy.

[92]  H. Schmitt.  New methods of delivery of amphotericin B. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[93]  C. Viscoli,et al.  Fluconazole in the treatment of candidiasis in immunocompromised children , 1991, Antimicrobial Agents and Chemotherapy.

[94]  D. Warnock.  Amphotericin B: an introduction. , 1991, The Journal of antimicrobial chemotherapy.

[95]  J. Adler-Moore,et al.  Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. , 1991, The Journal of antimicrobial chemotherapy.

[96]  D. Denning,et al.  Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. , 1990, Reviews of infectious diseases.

[97]  R. M. Tucker,et al.  Adverse events associated with itraconazole in 189 patients on chronic therapy. , 1990, The Journal of antimicrobial chemotherapy.

[98]  R. Diasio,et al.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. , 1987, The New England journal of medicine.

[99]  R. Diasio,et al.  Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. , 1987, The American journal of medicine.

[100]  D. Armstrong,et al.  Distribution and activity of amphotericin B in humans. , 1985, The Journal of infectious diseases.

[101]  J. Perfect,et al.  Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. , 1984, Reviews of infectious diseases.

[102]  D. Alling,et al.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. , 1979, The New England journal of medicine.

[103]  R. Diasio,et al.  Evidence for Conversion of 5-Fluorocytosine to 5-Fluorouracil in Humans: Possible Factor in 5-Fluorocytosine Clinical Toxicity , 1978, Antimicrobial Agents and Chemotherapy.

[104]  F. Firkin.  Therapy of deep-seated fungal infections with 5-fluorocytosine. , 1974, Australian and New Zealand journal of medicine.

[105]  V. Devita,et al.  Aspergillosis. The spectrum of the disease in 98 patients. , 1970, Medicine.

[106]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.